NeoGenomics, Inc.

DB:NG9 Stock Report

Market Cap: €1.8b

NeoGenomics Future Growth

Future criteria checks 1/6

NeoGenomics is forecast to grow earnings and revenue by 32.1% and 10.1% per annum respectively. EPS is expected to grow by 34.3% per annum. Return on equity is forecast to be 6.1% in 3 years.

Key information

32.1%

Earnings growth rate

34.3%

EPS growth rate

Healthcare earnings growth27.7%
Revenue growth rate10.1%
Future return on equity6.1%
Analyst coverage

Good

Last updated11 Nov 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:NG9 - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026800-374N/A8
12/31/2025727-54-28N/A13
12/31/2024662-80-58N/A13
9/30/2024644-78-2215N/A
6/30/2024628-79-300N/A
3/31/2024611-84-40-15N/A
12/31/2023592-88-31-2N/A
9/30/2023575-96-50-23N/A
6/30/2023552-115-64-34N/A
3/31/2023530-126-82-50N/A
12/31/2022510-144-97-66N/A
9/30/2022497-163-120-82N/A
6/30/2022489-147-119-74N/A
3/31/2022486-36-115-58N/A
12/31/2021484-8-91-27N/A
9/30/202148549-65-1N/A
6/30/202148972-497N/A
3/31/2021454-11-3011N/A
12/31/20204444-281N/A
9/30/2020425-5-25-1N/A
6/30/2020405-5-617N/A
3/31/20204193-1110N/A
12/31/20194098323N/A
9/30/201937821835N/A
6/30/201934321325N/A
3/31/201930962437N/A
12/31/201827763045N/A
9/30/201826282035N/A
6/30/2018252-1N/A34N/A
3/31/2018246-9N/A34N/A
12/31/2017240-11N/A18N/A
9/30/2017239-27N/A12N/A
6/30/2017241-26N/A14N/A
3/31/2017242-29N/A13N/A
12/31/2016232-31N/A21N/A
9/30/2016211-18N/A24N/A
6/30/2016175-12N/A17N/A
3/31/2016136-7N/A14N/A
12/31/2015100-3N/A6N/A
9/30/2015980N/A5N/A
6/30/2015960N/A6N/A
3/31/2015920N/A8N/A
12/31/2014871N/A9N/A
9/30/2014801N/A8N/A
6/30/2014742N/A7N/A
3/31/2014692N/A5N/A
12/31/2013662N/A2N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: NG9 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: NG9 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: NG9 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: NG9's revenue (10.1% per year) is forecast to grow faster than the German market (5.6% per year).

High Growth Revenue: NG9's revenue (10.1% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: NG9's Return on Equity is forecast to be low in 3 years time (6.1%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y